Recent News for OVID - Ovid Therapeutics Inc.

Date Title
Nov 16 Granite Point Capital’s Returns, AUM, and Holdings
Nov 15 Raymond James likes Galapagos in premarket analyst action
Nov 15 The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Nov 14 Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
Nov 8 Ovid Therapeutics reports Q3 results
Nov 8 Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress
Oct 31 The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
Oct 25 Ovid to host CC on new data on OV101 in Angelman syndrome
Oct 25 Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting
Oct 22 Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community
Oct 22 Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT
Oct 19 Key events next week - healthcare
Sep 24 Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
Sep 19 Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018
Sep 6 Ovid Therapeutics (OVID) Presents At Baird's Global Healthcare Conference - Slideshow
Sep 5 OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?
Sep 4 Ovid Therapeutics CFO to depart September 21
Sep 4 Dr. Yaron Werber, Chief Business and Financial Officer, to Return to Wall Street
Aug 29 Ovid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018
Aug 23 FDA OKs new treatment for Dravet syndrome
Aug 16 Ovid Therapeutics Announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child And Adolescent Psychiatry Annual Meeting
Aug 9 Ovid Therapeutics beats by $0.07
Aug 9 Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress
Aug 7 Ovid Therapeutics (OVID) OV101 Phase 2 Trial Data - Slideshow
Aug 7 52 Biggest Movers From Yesterday

Back to the Main OVID Page...